



881

United States Patent and Trademark Office

STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

MAY 3 0 2007

ATTY. DOCKET NO.

10/583,034

Phillipe Gauthier

P08951US00BAS

INTERNATIONAL APPLICATION NO.

PCT/IB04/04096

I.A. FILING DATE

PRIORITY DATE

12/14/2004

12/17/2003

STITES & HARBISON PLLC 1199 NORTH FAIRFAX STREET SUITE 900 ALEXANDRIA, VA 22314

RECEIVED

MAY 0 2 2007

CONFIRMATION NO. 6756 371 FORMALITIES LETTER

OC000000023617889

Date Mailed: 05/01/2007

STITES & HARBISON PLLC

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/Authenticate/SerLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

KAREN R MCLEAN

Telephone: (703) 308-9140 EXT 214

PART 1 - ATTORNEY/APPLICANT COPY

	U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/583,034		PCT/IB04/04096	P08951US00BAS

FORM PCT/DO/EO/922 (371 Formalities Notice)



Drug Box

Ţ!	Application #	10/583,034	/ 4
TO ANOMITTAL FORM	Confirmation #	6756	1
TRANSMITTAL FORM	Filing Date	15 June 2006	MAY 3 0 2007
` /	First Inventor	GAUTHIER	1
(for all correspondence after initial filing)	Art Unit		7470 1940
Fig. 1	Examiner		MOEMA
Total number of pages in this submission =	Docket #	P08951US00/BAS	

ENCLOSURES (check all that apply)						
☐ Fees calculated below ☐ Amendment/Reply ☐ including Attachment(s) ☐ After Final Amendment/Reply ☐ including Attachment(s) ☑ Preliminary Amendment and Statement Regarding Sequence Listing ☑ Diskette	 □ Reply to Missing Parts/Incomplete Application □ Certified Copy of Priority Document(s) □ Information Disclosure Statement □ Drawing(s) □ Terminal Disclaimer □ Copy of Notice 					
FEES CALCULATION: For claims if required and/or other fees as shown below:						

FEES CALCULATION: For claims if required and/or other fees as shown below:							
	NOW	Previously Paid For	Present Extra	Rate	<u>\$</u>		
☐ TOTAL CLAIMS		- 20		X \$ 50 =			
☐ INDEPENDENT CLAIMS		- 3		X \$ 200 =			
TOTAL OF ABOVE CLAIMS FEES =							
Reduction by ½ for small entity status of applicant							
SUBTOTAL =							
☐ Fee for extension of time (per attached Petition) ☐Other fee for							
TOTAL OF ALL FEES =							

Payment by credit card. FORM PTO-2038 in the amount of \$\\$ is attached.

The Director is authorized to charge any fee, additional fee or extension fee due in connection herewith to Deposit Account No. 12-0555:

(1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or

(2) if no petition for extension of time is enclosed but an EOT is required - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely.

Date: May 30, 2007

By: B. Aaron Schulman Registration No.: 31,877

STITES & HARBISON PLLC ◆ 1199 North Fairfax St. ◆ Suite 900 ◆ Alexandria, VA 22314 TEL: 703-739-4900 ◆ FAX: 703-739-9577 ◆ Customer No. 00881